Corporate Governance: Ongoing corporate governance can be a daunting task for a life sciences aspiring company, but our team can help you make the process more manageable. Members of the Goodwin Life Sciences team often act as general counsel for emerging life sciences companies, advising them on a variety of ongoing legal matters. For example, our team can help draft and review all types of corporate agreements, advise on employment and benefits issues, and help prepare for board meetings and attend board meetings. As European life sciences companies seek opportunities in the European and US markets, it is essential to have a business partner with local support and experience in both regions. Goodwin`s team of life sciences lawyers spans the east to the west coast of the United States and is strategically located in key European centers to advise European life sciences companies on the full range of legal needs. Our life sciences patent attorneys work hand-in-hand with our strong corporate governance, financing and intellectual property litigation teams to ensure the best IP strategy is in place to drive business and product growth and mitigate risk. Michael Shuster has extensive intellectual property expertise covering patenting and transactional intellectual property matters on behalf of emerging and established life sciences companies. Very solid and well known. Nancy Urizar, Partner: I enjoy working directly with clients to advise them on how to achieve their business goals. It is very rewarding to be able to help a client establish a cooperative relationship with a counterpart so that they can work together to develop and commercialize a technology that saves lives. Litigation in the pharmaceutical and biotechnology industries can be particularly complex and requires advice that knows both scientific disciplines and law. Goodwin has made meeting the needs of the pharmaceutical and biotechnology industries a strategic priority for more than two decades, and we have one of the largest and most active life sciences practices in the United States. Our intellectual property litigation team is among the most experienced in the country and successfully represents branded and generic companies in Hatch-Waxman litigation. Our client portfolio includes some of the world`s largest innovators and generics companies, and we have represented our clients in patent cases involving some of the world`s largest blockbuster medicines.
With more than 150 lawyers dedicated to serving more than 600 life sciences clients, our integrated, full-service life sciences team provides deep transaction expertise backed by corporate resources around the world. Over the past five years, Goodwin has completed more than 95 IPOs for $41 billion in stock and has also worked on more than 550 public offerings with more than $135 billion in equity. CA: What are the differences between non-litigious and contentious work in the life sciences? Goodwin Labs is a new initiative to support emerging life sciences companies. Goodwin Labs provides legal services and complementary educational content to early-stage life sciences companies through partnerships with startup incubators and accelerators. Both employees join the company in Washington, D.C. Over the past year, the company`s healthcare and life sciences practice contributed significantly to the company`s profits. In 2020, Goodwin recorded revenue growth of 11.7% and earnings per partner of 10.6%. Other companies, such as Fenwick & West and Cooley, also saw life sciences catapult them to profit increases of more than 20% last year. ST: Since the beginning of the pandemic, nothing has been deeper than the commitment and resilience of those working in life sciences and healthcare. While private-sector innovators worked at a breakneck pace to meet the needs of patients and providers with new vaccines, treatments, and diagnostics, FDA staff worked the same way 24/7. ensure rapid access to these critical medical devices. is an essential component for all life sciences companies.
Our patent attorneys, patent attorneys and life sciences technical staff ensure that the best IP strategy is in place to position and secure the protection of intellectual property, including patent protection, of our clients` core technology and manage therapeutic units, including small molecules, biologics, formulations, delivery systems, companion diagnostics and medical devices. We have extensive experience in IP review and patent landscape valuation to assist our clients, including operating companies, investors and financial institutions, with financing events, including public offerings and private financings, and to consolidate IP positions for acquisitions or other exit strategies. Succeeding in the life sciences industry is a matter of strategy and execution as well as research and development. And with the rapid pace of technology revolutionizing industries globally, Goodwin`s extensive experience not only in life sciences, but also working with our technology, healthcare, real estate and private equity lawyers, makes our team uniquely qualified to handle whatever the future holds. Our life sciences lawyers work with their clients to harness the promise and potential of innovation to make a profound and lasting impact. NU: The most interesting deals I work on are those where I work closely with the client to provide advice that moves a transaction forward. It is very rewarding when a transaction is closed and the parties involved can then lead the development and commercialization of vital technologies. It`s a go-getter culture, but it`s not ruthless – Learn life as a junior partner at Goodwin. Sam Zucker is well versed in representing companies and investors in life sciences, healthcare and technology transactions. Clark Zhang, Partner: There are a variety of areas of activity, ranging from corporations to intellectual property (e.g., patenting, patent litigation, licensing, trademarks).
In patenting processes, for example, life sciences include small molecules, biologics, and even computer applications of the life sciences. Chambers Associate: What are the areas of activity in the life sciences sector? Since the four user fee agreements for medical devices — those for medical devices, drugs/biologics, generics, and biologics — all expire at the end of September 2022, the legislator must pass reauthorization packages to ensure program continuity at the FDA. Topics ranged from possible changes to expedited regulatory authorities for prescription drugs, to the pilot project for the Full Product Life Cycle Consultation Program for medical devices, to legislative proposals that would revise the FDA`s framework for regulating in vitro diagnostics and laboratory-developed tests. We are leaders in meeting the needs of companies ranging from pure start-ups to commercial-stage biopharmaceuticals and everything in between, as well as investors, banks and all the other companies in the life sciences ecosystem that support these companies.